
Bristol-Myers Squibb, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan Seigerman from BMO Capital maintained a Hold rating on the stock and has a
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| BMY | Bristol-Myers Squibb | 58.80 | 14.52 | 32.79% |
| Name | Price | % Change | |
|---|---|---|---|
| $58.80 | +32.79% |

Bristol-Myers Squibb, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan Seigerman from BMO Capital maintained a Hold rating on the stock and has a

Evotec (EVO) announced that its strategic protein degradation partnership with Bristol Myers (BMY) has received a second investigational new drug, or IND, acceptance from the FDA. The first candidate produced

Bristol Myers (BMY) Squibb announced preliminary Phase 3 findings of short- and long-term KarXT treatment from the 12-week open-label period of the ADEPT-1 study and the 52-week open-label extension ADEPT-3

Erasca (ERAS) announced a clinical trial collaboration and supply agreement, or CTCSA, with Bristol Myers Squibb (BMY) to evaluate Erasca’s potentially best-in-class pan-RAS molecular glue, ERAS-0015, with navlimetostat, BMS’s investigational

Bearish flow noted in Bristol Myers (BMY) Squibb with 9,084 puts trading, or 1.7x expected. Most active are Nov-26 61 puts and Nov-26 60 puts, with total volume in those

Analyst Evan Seigerman of BMO Capital maintained a Hold rating on Bristol-Myers Squibb, retaining the price target of $60.00. Evan Seigerman’s rating is based on a balance between encouraging clinical

Bristol Myers (BMY) Squibb presented 56-week results from the Phase 3 SCOUT-HCM clinical trial in a late-breaker presentation at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions, taking place November 6,

Bearish flow noted in Bristol Myers (BMY) Squibb with 8,291 puts trading, or 3x expected. Most active are 11/6 weekly 60 puts and 11/6 weekly 59 puts, with total volume

Unusual total active option classes on open include: HDFC Bank (HDB), Allstate (ALL), Consumer Staples Sector SPDR ETF (XLP), Bristol Myers Squibb (BMY), Lam Research (LRCX), Mini SPX (.XSP), Tradr

Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers Squibb’s NCT07024862 is officially titled “Long-Term Real-World Outcomes Among Patients With Programmed Death-Ligand 1 (PD-L1)
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| hold | Reiterated | Nov 19, 2026 | ||||
| hold | Reiterated | Nov 18, 2026 | ||||
| buy | Reiterated | Nov 16, 2026 | ||||
| hold | Reiterated | Nov 5, 2026 | ||||
| hold | Reiterated | Nov 2, 2026 | ||||
| hold | Reiterated | Oct 30, 2026 | ||||
| sell | Reiterated | Oct 30, 2026 | ||||
| hold | Reiterated | Oct 30, 2026 | ||||
| buy | Reiterated | Oct 29, 2026 | ||||
| buy | Reiterated | Oct 29, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Feb 4, 2027TBA | $120.19B | $1.50 | $12.66B | -0.09 | 13.01 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.